Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells

• Published in: Nanomaterials (Basel, Switzerland) Switzerland), 2022-11, Vol.12 (22), p.4029
• Main Authors: Jamal, Alam, Asseri, Amer H, Ali, Ehab M M, El-Gowily, Afnan H, Khan, Mohamed Imran, Hosawi, Salman, Alsolami, Reem, Ahmed, Tarek A
• Format: Article
• Language: English
• Subjects: 6-Mercaptopurine; Anticancer properties; Apoptosis; Cancer; Cancer cells; Cancer therapies; Care and treatment; Cell cycle; cell cycle phases; Cell growth; Cell proliferation; Comparative analysis; Cytotoxicity; DNA biosynthesis; DNA synthesis; Drug delivery; Drug delivery systems; Drugs; Entrapment; Ethanol; FDA approval; human cell lines; Hydration; IC50; Immune system; Lipids; Liposomes; Mercaptopurine; Nanoparticles; Polydispersity; Priming; S phase; Thin films; Toxicity; Vehicles; Zeta potential
• ISSN: 2079-4991; 2079-4991
• DOI: 10.3390/nano12224029

6-Mercaptopurine (6-MP) is a well-known immunosuppressive medication with proven anti-proliferative activities. 6-MP possesses incomplete and highly variable oral absorption due to its poor water solubility, which might reduce its anti-cancer properties. To overcome these negative effects, we developed neutral and positively charged drug-loaded liposomal formulations utilizing the thin-film hydration technique. The prepared liposomal formulations were characterized for their size, polydispersity index (PDI), zeta potential, and entrapment efficiency. The average size of the prepared liposomes was between 574.67 ± 37.29 and 660.47 ± 44.32 nm. Positively charged liposomes (F1 and F3) exhibited a lower PDI than the corresponding neutrally charged ones (F2 and F4). Entrapment efficiency was higher in the neutral liposomes when compared to the charged formulation. F1 showed the lowest IC against HepG2, HCT116, and MCF-7 cancer cells. HepG2 cells treated with F1 showed the highest level of inhibition of cell proliferation with no evidence of apoptosis. Cell cycle analysis showed an increase in the G1/G0 and S phases, along with a decrease in the G2/M phases in the cell lines treated with drug loaded positively charged liposomes when compared to free positive liposomes, indicating arrest of cells in the S phase due to the stoppage of priming and DNA synthesis outside the mitotic phase. As a result, liposomes could be considered as an effective drug delivery system for treatment of a variety of cancers; they provide a chance that a nanoformulation of 6-MP will boost the cytotoxicity of the drug in a small pharmacological dose which provides a dosage advantage.